Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053021 | 0.91 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL17653793 | 0.90 | AGTR1 (0.54) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6891884 | 0.90 | AGTR1 (0.56) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8791723 | 0.90 | AGTR1 (0.49) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL13755335 | 0.89 | AGTR1 (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8791379 | 0.88 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL1237602 | 0.88 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL10021557 | 0.88 | AGTR1 (0.53) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL1472569 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL60 | 0.88 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102036953-B | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2015-05-06 | — | — | CN | claimed |
| CN-102036953-A | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2011-04-27 | — | — | CN | claimed |
| CN-103906509-B | Enkephalinase inhibitor | 施万生物制药研发IP有限责任公司 | 2016-11-02 | — | — | CN | disclosed |
| CN-105061314-A | Neprilysin inhibitors | THERAVANCE INC | 2015-11-18 | — | — | CN | disclosed |
| CN-103261164-B | Enkephalinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-19 | — | — | CN | disclosed |
| CN-103420877-B | Based on the selectivity MMP inhibitor of hydroxamic acid ester | NOVARTIS AG (CH) | 2015-08-12 | — | — | CN | disclosed |
| CN-103748070-B | Enkephalinase inhibitors | THERAVANCE INC | 2015-06-24 | — | — | CN | disclosed |
| CN-102036953-B | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-101657424-B | Dual-action antihypertensive agent | THERAVANCE INC US | 2014-09-24 | — | — | CN | disclosed |
| CN-103906509-A | Enkephalinase inhibitors | THERAVANCE INC | 2014-07-02 | — | — | CN | disclosed |
| CN-103748070-A | Enkephalinase inhibitors | THERAVANCE INC | 2014-04-23 | — | — | CN | disclosed |
| CN-101657424-A | Dual-action antihypertensive agent | THERAVANCE INC US | 2010-02-24 | — | — | CN | disclosed |
| EP-2146963-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| CN-101410370-A | Selective hydroxamate-based MMP inhibitors | NOVARTIS AG (CH) | 2009-04-15 | — | — | CN | disclosed |
| CN-101326166-A | Novel N-sulfamoyl-piperidine amides for the prevention or treatment of obesity and related disorders | SOLVAY PHARM GMBH (DE) | 2008-12-17 | — | — | CN | disclosed |
| WO-2008133896-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| CN-1997370-A | Medicaments containing N-sulfamoyl-N' -arylpiperazines for the prophylaxis or treatment of obesity and related diseases | SOLVAY PHARM GMBH (DE) | 2007-07-11 | — | — | CN | disclosed |
| EP-0652869-B1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY | LUSO FARMACO INST (IT) | 1997-03-26 | — | — | EP | disclosed |
| US-5538987-A | Imidazole ethers having a II antagonist activity | ISTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1996-07-23 | — | — | US | disclosed |
| WO-1994002467-A1 | IMIDAZOLE ETHERS HAVING A II ANTAGONIST ACTIVITY | INSTITUTO LUSO FARMACO D'ITALIA S.P.A. (IT) | 1994-02-03 | — | — | WO | disclosed |